Rifat Pamukcu
Director · Aprea Therapeutics, Inc.
Individual
- 2026
- Jun 17, 2026
- 1
Filings (90d)
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Rifat Pamukcu files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Richard Peters - $100K in APRE purchases and sales in the last 12 months
- John P. Hamill - $30K in APRE purchases and sales in the last 12 months
- Oren Gilad - $25K in APRE purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Rifat Pamukcu?
Rifat Pamukcu is a corporate insider, tracked as Director of Aprea Therapeutics, Inc. (APRE). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Rifat Pamukcu last file a Form 4?
The only primary Form 4 on record is dated 17 June 2026.
